Bjorn Henning Gronberg

Academic History

Bjorn Henning Gronberg, MD, PhD, is a Professor of Clinical and Molecular Medicine at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. He leads both the Cancer and Palliative Care Research Group and the Translational Cancer Research Unit within the Department of Clinical and Molecular Medicine. Prof. Gronberg earned his medical degree from the University of Bergen, Bergen, Norway, and completed his specialist training in oncology at St. Olavs Hospital, Trondheim, Norway, where he continues to serve as a consultant in oncology. He later earned his PhD in Clinical Medicine from NTNU.

Alongside his clinical and academic roles, he is a member of the Norwegian Board of Medical Experts for Patients with Life-Threatening Diseases. He is also actively involved in national and international oncology societies, including the Norwegian Lung Cancer Study Group (NLCG), the International Association for the Study of Lung Cancer (IASLC), the American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO).

Speaking on clinical trials and biomarker research in SCLC

Prof. Gronberg specializes in small-cell lung cancer (SCLC), with a focus on clinical trials evaluating new treatment strategies, including radiotherapy and immunotherapy. He also serves as PI for multiple randomized studies assessing therapeutic outcomes in both limited and extensive-stage SCLC. His translational research explores the predictive and prognostic value of biomarkers such as ctDNA and microRNA, aiming to personalize treatment. He also investigates how comorbidity, frailty, and functional status influence cancer care, particularly in older patients.